Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old
Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a ...
Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU
Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU Confirming the results of CUPID-A, this second ...
Pharmabiz9d
Dupixent data reinforce clinically meaningful benefit from pooled analysis of two COPD phase 3 studies
Dupixent data reinforce clinically meaningful benefit from pooled analysis of two COPD phase 3 studies: Paris Wednesday, September 11, 2024, 16:00 Hrs [IST] A pooled analysis from ...
PipelineReview.com8d
Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU
PARIS, France and TARRYTOWN, NY, USA I 11, 2024 I A Dupixent (dupilumab) confirmatory phase 3 study (LIBERTY-CUPID Study C) met the primary and key ...
sanofi10d
Media Update: ERS: Dupixent data reinforce clinically meaningful benefit from pooled analysis of two COPD phase 3 studies
ERS: Dupixent data reinforce clinically meaningful benefit from pooled analysis of two COPD phase 3 studies Pooled results from the BOREAS and NOTUS studies show meaningful clinical benefit ...
Sanofi: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU
Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU Confirming the results of CUPID-A, this second pivotal study in biologic-naïve patients met primary ...